Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in Transcode Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +6 vs. Q3 2022
- Shares held
- 345.2K
- −1.71M (−83.2%) vs. Q3 2022
- Total value
- $222.5K
- −$2.04M (−90.2%) vs. Q3 2022
- New holders
- 12
- 3 more added
- Sold out
- 6
- 0 more reduced
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAZ on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $208.1K |
| Q1 2026 | 8 | $265.7K |
| Q4 2025 | 6 | $26.4K |
| Q3 2025 | 8 | $155.0K |
| Q2 2025 | 9 | $237.0K |
| Q1 2025 | 19 | $1.06M |
| Q4 2024 | 5 | $33.4K |
| Q3 2024 | 10 | $185.8K |
| Q2 2024 | 15 | $263.0K |
| Q1 2024 | 7 | $284.1K |
| Q4 2023 | 13 | $105.4K |
| Q3 2023 | 11 | $281.6K |
| Q2 2023 | 5 | $476.6K |
| Q1 2023 | 11 | $88.6K |
| Q4 2022 | 18 | $222.5K |
| Q3 2022 | 13 | $2.27M |
| Q2 2022 | 13 | $2.67M |
| Q1 2022 | 13 | $3.14M |
| Q4 2021 | 16 | $5.98M |
| Q3 2021 | 17 | $7.28M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Transcode Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 76,549 | $51.0K | 0.00% | 00.0% | Unchanged |
| Cahill Wealth Management, LLC | 47,060 | $22.9K | 0.02% | +47,060 | New |
| HRT Financial LP | 25,995 | $17.0K | 0.00% | +25,995 | New |
| Sheets Smith Wealth Management | 25,000 | $16.8K | 0.00% | +25,000 | New |
| State Street Corp | 21,019 | $14.1K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 20,854 | $14.0K | 0.00% | +20,854 | New |
| Two Sigma Investments, LP | 19,407 | $13.1K | 0.00% | +19,407 | New |
| Goldman Sachs Group Inc | 17,122 | $11.5K | 0.00% | +17,122 | New |
| Virtu Financial LLC | 16,361 | $11.0K | 0.00% | +16,361 | New |
| BlackRock Inc. | 15,678 | $10.6K | 0.00% | +344+2.2% | Added |
| Shay Capital LLC | 15,060 | $10.1K | 0.01% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 13,500 | $9.00K | 0.00% | +13,500 | New |
| Millennium Management LLC | 12,880 | $9.00K | 0.00% | +12,880 | New |
| Triumph Capital Management | 10,000 | $6.73K | 0.00% | +10,000 | New |
| Tower Research Capital LLC (TRC) | 6,351 | $4.00K | 0.00% | +846+15.4% | Added |
| Morgan Stanley | 1,165 | $784 | 0.00% | +1,165 | New |
| UBS Group AG | 1,159 | $777 | 0.00% | +1,159 | New |
| Wells Fargo & Company | 50 | $34 | 0.00% | +1+2.0% | Added |
| AIGH Capital Management LLC | 0 | $0 | 0.00% | −1,289,000−100.0% | Sold out |
| Worth Venture Partners, LLC | 0 | $0 | 0.00% | −324,157−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −200,117−100.0% | Sold out |
| Redmond Asset Management, LLC | 0 | $0 | 0.00% | −90,874−100.0% | Sold out |
| K.J. Harrison & Partners Inc | 0 | $0 | 0.00% | −19,987−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −86−100.0% | Sold out |
| ACT Capital Management, LLC | – | – | – | – | Not filed |